TITLE:
Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

CONDITION:
Asthma

INTERVENTION:
Roflumilast

SUMMARY:

      The aim of the study is to compare the effects of oral roflumilast with placebo on lung
      function in patients with asthma.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 70 Years
Criteria:

        Main Inclusion Criteria:

          -  Persistent bronchial asthma

          -  No change in asthma treatment within 4 weeks prior to visit 1

          -  Non-smoker or ex-smoker (for 12 months or longer)

        Main Exclusion Criteria:

          -  Poorly controlled asthma or seasonal asthma

          -  History of lower airway infection four weeks prior to visit 1

          -  Chronic obstructive pulmonary disease (COPD) and/or other relevant lung disease

          -  Patients using > 8-puffs/day-short-acting bronchodilator (beta-agonists) (more than 3
             days per week on average) prior to visit 1

          -  Clinically relevant abnormal laboratory values suggesting an undiagnosed disease,
             severe renal insufficiency, active hepatitis or an HIV infection

          -  Diagnosis, treatment or remission of any cancer (other than basal cell carcinoma)
             within two years prior to visit 1

          -  Patients with chronic heart failure

          -  Suspected hypersensitivity and/or contraindication to roflumilast or
             albuterol/salbutamol

          -  Female patients of childbearing potential not using adequate means of birth control
             or pregnant or breast-feeding females

          -  Patients who have received any investigational medication or device in the month
             prior to visit 1 or who plan to use another investigational medication during the
             study
      
